Tuesday, January 6, 2015

Next Generation Protein Therapeutics Summit: Preliminary Agenda

IBC’s 10th Annual Next Generation Protein Therapeutics Summit delivers the very latest results from an ever expanding number of multifunctional molecules in development and offers you the best opportunity to learn from world-renowned academics and industry visionaries who are expanding the frontiers of biologic drugs.  It will take place May 18-20, 2015 in San Francisco, CA.

This Summit is the industry’s most comprehensive conference for sharing new ideas to accelerate the discovery, engineering and development of alternative scaffolds and novel protein therapeutics to create differentiated drugs. By attending, you will gain valuable knowledge from more than 40 presentations showcasing new, unpublished data and exclusive case studies, including lessons learned from the most-recently approved ADCs and Bispecific therapeutics.

Agenda Sessions:
  • • Recent Advances in Discovery Technologies
  • • Development of Immunotherapies
  • • Creative Protein Engineering and Design Approaches
  • • Next Generation Bioconjugates
  • • Unlocking New Biology with Novel Scaffolds and Antibody Fragments as Therapeutics
  • • Addressing Difficult Targets with Protein Therapeutics
  • • Delivery of Proteins
  • • Emerging Methods and Technologies for Screening, Selection and Sequencing
  • • Novel Therapeutic Peptide Development
  • • Bispecific and Multispecifics - New Advances and Approaches
  • • Bispecific and Multispecifics - Engineering Developability into Multi-Functional Protein Therapeutics
  • • Bispecific and Multispecifics - Clinical Case Studies
  • • Molecular Imaging
  • • Aggregation and Immunogenicity

Confirmed Speakers Include:
  • • Peter Senter, Ph.D., Vice President, Chemistry, Seattle Genetics
  • • Jennifer Cochran, Ph.D., Associate Professor of Bioengineering and Chemical Engineering, Stanford University
  • • K. Dane Wittrup, Professor, Chemical Engineering & Biological Engineering, MIT
  • • Gary Starling, Ph.D., Associate Vice President, Biologics Discovery Operations, Merck
  • • Robert Lutz, Ph.D., Vice President, Translational Research and Development, ImmunoGen, Inc.
  • • Robyn Barfield, Ph.D. Group Leader, Bioconjugation, Catalent Pharma Solutions
  • • Dimiter Dimitrov, Ph.D., Senior Investigator, Protein Interactions, National Cancer Institute, NIH
  • • Arne Skerra, Ph.D., Chief Scientific Officer, XL Protein
  • • Dasa Lipovsek, Ph.D., Senior Principal Scientist, Bristol-Myers Squibb
  • • David Urech, Ph.D., Co-CEO and Chief Scientific Officer, Numab, Switzerland
  • • Joachim Feldwisch, Ph.D., Director Preclinical Development, Affibody Ab, Sweden
  • • Catherine Hutchings, Ph.D., Antibody Alliance Management & Strategic Partnering, Heptares Therapeutics Ltd., United Kingdom
  • • Andrew Bradbury, Ph.D., Ph.D., Research Scientist and Team Leader, Los Alamos
  • • Patrick Baeuerle, Vice President, Research; General Manager, Amgen Research GmbH, Germany
  • • Aaron Sato, Ph.D., Vice President of Research, Sutro Biopharma
  • • Volker Schellenberger, Ph.D., President and CEO, Amunix
  • • Zhenping Zhu, MD, Ph.D., Executive Vice President, Global Biopharmaceuticals, Kadmon Corporation
  • • Kaspar Binz, Ph.D., Vice President and Co-Founder, Molecular Partners AG, Switzerland
  • • Olivier Laurent, Ph.D., Vice President, CMC, Ambrx
  • • Steven Jacobs, Ph.D., Associate Scientific Director, Biologics Research, Janssen R&D
  • • Antonin de Fougerolles, Ph.D., Chief Scientific Officer, Ablynx, Belgium
  • • Dragan Grabulovski, Ph.D., Chief Scientific Officer, Covagen AG, Switzerland
  • • Fredrik Frejd, Ph.D., Chief Scientific Officer, Affibody AB, Sweden
  • • Bradley Pentelute, Ph.D., Assistant Professor, MIT
  • • Jean E. Lachowicz, Ph.D., Chief Scientific Officer, Angiochem
  • • Mark Dennis, Ph.D., Principal Scientist, Antibody Engineering, Genentech, Inc.
  • • Gregory C. Ippolito, Ph.D., Research Assistant Professor, Department of Molecular Biosciences, The University of Texas at Austin
This event is taking place on May 18-20, 2015 in San Francisco, CA is co-located with IBC's Bioconjugates: From Targets to Therapeutics and Cell Line Development & Engineering conferences. With these 3 established events, under one roof – you can cross-fertilize with multiple disciplines to gain new ideas to help you propel promising candidates toward commercial success. Find out more about attending all three events with our Best Value All Access Pass.

Share this article with your social network, just click below to share now!

No comments :

Post a Comment